Form 4 for TWST Twist Bioscience Corp
Accepted 2026-06-01 16:05:09 ET · period of report 2026-05-28 · accession 0001214659-26-006967 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-01 16:05 | 2026-05-28 | TWST | Leproust Emily M. | CEO, Dir | M - OptEx | $8.82 | +16.5K | 863.3K | +2% | +$145.3K |
| DMT | 2026-06-01 16:05 | 2026-05-28 | TWST | Leproust Emily M. | CEO, Dir | S - Sale+OE | $67.91 | -16.5K | 846.9K | -2% | -$1.12M |
| DT | 2026-06-01 16:05 | 2026-05-28 | TWST | Leproust Emily M. | CEO, Dir | M - OptEx | $0.00 | -16.5K | 75.4K | -18% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-28 | M | A | 16,470 | $8.82 | 863,342 | D | — | — | (F1) The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. |
| 2 | Common | Common Stock | 2026-05-28 | S | D | 1,482 | $65.33 | 861,860 | D | — | — | (F1) The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. (F2) Represents the weighted average sales price per share. The shares sold at prices ranging from $65.00 to $65.820 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| 3 | Common | Common Stock | 2026-05-28 | S | D | 900 | $66.85 | 860,960 | D | — | — | (F1) The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. (F3) Represents the weighted average sales price per share. The shares sold at prices ranging from $66.240 to $67.210 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| 4 | Common | Common Stock | 2026-05-28 | S | D | 7,623 | $67.95 | 853,337 | D | — | — | (F1) The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. (F4) Represents the weighted average sales price per share. The shares sold at prices ranging from $67.240 to $68.2375 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| 5 | Common | Common Stock | 2026-05-28 | S | D | 6,465 | $68.61 | 846,872 | D | — | — | (F1) The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. (F5) Represents the weighted average sales price per share. The shares sold at prices ranging from $68.240 to $69.190 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| 6 | Derivative | Employee Stock Option (right to buy) | 2026-05-28 | M | D | 16,470 | $0.00 | 75,439 | D | $8.82 · — to 2027-09-28 | 16,470 Common Stock | (F10) The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. |